| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Schreiber, Olof, 1980-, et al.
(författare)
-
Influence of Lactobacillus reuteri on the colonic microbiota in health and DSS-induced colitis
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Aim: To investigate the impact of Lactobacillus reuteri and Dextran Sulphate Sodium (DSS) on the colonic microbiota by investigating bacterial content and composition in the individual colonic mucus layers and mesenteric lymph nodes. Methods: Rats were divided into 4 groups: control, L. reuteri, DSS and L. reuteri+DSS. L. reuteri was given as a cocktail containing 109 cfu of four different strains of L. reuteri by gavage daily for 16 days. Colitis was induced by 5% DSS in the drinking water for 9 days. The firmly and loosely mucus layers and mesenteric lymph nodes were collected, homogenized and its bacterial content was monitored using both culturing as well as the molecular method terminal restriction fragment length polymorphism (TRFLP). Results: In controls, the number of bacteria was significantly lower in the inner firmly adherent mucus layer than the outer loosely adherent layer, indicating a barrier function of the inner mucus layer. The composition of the microbiota was also different between layers. L. reuteri prevented colitis but did not alter the microbiota. DSS obliterated the differences between mucus layers both in terms of number of bacteria, and bacterial composition, indicating that DSS destroys the mucus regardless of the addition of L. reuteri. L. reuteri did however significantly decrease bacterial translocation in the DSS-model. Conclusion: The firmly adherent mucus layer serves as a barrier towards luminal bacteria. DSS alters the colonic microbiota and destroys the mucus barrier. L. reuteri ameliorates DSS-colitis by decreasing bacterial translocation.
|
|
| 5. |
- von Heideman, Anne, 1956-, et al.
(författare)
-
Assessment of Chemotherapeutic Drug Sensitivity in Epithelial Ovarian Cancer Using Primary Cultures of Tumour Cells from Patients
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Sensitivity of epithelial ovarian cancer to chemotherapeutic drugs relevant in treatment of this cancer type was analysed in 125 tumour samples from 112 patients using a short-term primary culture assay based on the concept of total cell kill. Sensitivity was related to histopathological subtypes, treatment status and clinical tumour response. For cisplatin, doxorubicin, 5-FU, cyclophosphamide and topotecan, seropapillary high grade and clear cell ovarian cancer were the most sensitive subtypes and the mucinous tumours the most resistant subtype, whereas endometrioid tumours and the seropapillary low grade/borderline tumours showed intermediate sensitivity. In contrast, docetaxel showed the opposite pattern of activity. Samples from patients previously treated with chemotherapy tended, for the majority of drugs, to be slightly more resistant than samples from treatment naïve patients. The activity of cisplatin correlated strongly with that of the other drugs with the exception of docetaxel, implicating non-cross resistance between these key drugs in ovarian cancer. Tumour samples from two sites in the same patient at the same occasion showed similar and samples taken at different occasions different cisplatin sensitivity, which may implicate tumour clonal selection over time. At group level, samples from patients clinically responding to treatment were more sensitive to most drugs than samples from non-responding patients. At the individual patient level, optimized analyses of drug sensitivity in vitro compared with clinical response showed sensitivities and specificities in the 90 – 100% and 54 – 83% ranges, respectively. In conclusion, ovarian cancer subtypes exhibit different chemotherapeutic drug sensitivity in vitro, which needs consideration in treatment decisions for this disease. Furthermore, in vitro assessment of ovarian cancer tumour cell chemotherapeutic drug sensitivity provides clinically relevant information that could be useful in efforts to optimize treatment in individual patients with this disease.
|
|
